Advertisement

Long-term dupilumab treatment for chronic refractory generalized prurigo nodularis: A retrospective cohort study

Published:February 18, 2021DOI:https://doi.org/10.1016/j.jaad.2021.02.038
      To the Editor: Dupilumab is under study for generalized prurigo nodularis (PN); however, the evidence is limited to case series with short follow ups.
      • Mollanazar N.K.
      • Elgash M.
      • Weaver L.
      • Valdes-Rodriguez R.
      • Hsu S.
      Reduced itch associated with dupilumab treatment in 4 patients with prurigo nodularis.
      • Calugareanu A.
      • Jachiet M.
      • Tauber M.
      • et al.
      Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients.
      • Napolitano M.
      • Fabbrocini G.
      • Scalvenzi M.
      • Nisticò S.P.
      • Dastoli S.
      • Patruno C.
      Effectiveness of dupilumab for the treatment of generalized Prurigo nodularis phenotype of adult atopic dermatitis.
      A recent retrospective study by Chiricozzi et al
      • Chiricozzi A.
      • Maurelli M.
      • Gori N.
      • et al.
      Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo.
      of an Italian cohort demonstrated short-term (36 weeks) improvement in itch and PN lesions when treating with dupilumab. We aimed to describe the long-term effectiveness and tolerability of dupilumab in treating generalized PN and further identify the characteristics of this patient population.
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mollanazar N.K.
        • Elgash M.
        • Weaver L.
        • Valdes-Rodriguez R.
        • Hsu S.
        Reduced itch associated with dupilumab treatment in 4 patients with prurigo nodularis.
        JAMA Dermatol. 2019; 155: 121-122
        • Calugareanu A.
        • Jachiet M.
        • Tauber M.
        • et al.
        Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients.
        J Eur Acad Dermatol Venereol. 2020; 34: e74-e76
        • Napolitano M.
        • Fabbrocini G.
        • Scalvenzi M.
        • Nisticò S.P.
        • Dastoli S.
        • Patruno C.
        Effectiveness of dupilumab for the treatment of generalized Prurigo nodularis phenotype of adult atopic dermatitis.
        Dermatitis. 2020; 31: 81-84
        • Chiricozzi A.
        • Maurelli M.
        • Gori N.
        • et al.
        Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo.
        J Am Acad Dermatol. 2020; 83: 39-45
        • Zeidler C.
        • Pereira M.P.
        • Augustin M.
        • Spellman M.
        • Ständer S.
        Investigator's Global Assessment of chronic prurigo: a new instrument for use in clinical trials.
        Acta Derm Venereol. 2021; 101: adv00401https://doi.org/10.2340/00015555-3701